Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2013 Filed May 1, 2013 19:46 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
Exercise / conversionRestricted Stock Unit · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-023302 · doc4.xml · derivative · entry 4 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2013-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2013 Filed May 1, 2013 19:46 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
Tax withholdingCommon Stock | 4,698 | $55.38 | $260,175.24 |
DisclosureSEC source: 0001209191-13-023302 · doc4.xml · nonDerivative · entry 2 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,177 Read SEC document |
| May 01, 2013 Filed May 1, 2013 19:46 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-023302 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2013 Filed May 1, 2013 19:40 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 152 | $56.49 | $8,586.48 |
DisclosureSEC source: 0001209191-13-023297 · doc4.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,340 Read SEC document |
| April 29, 2013 Filed Apr 29, 2013 17:08 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
SaleCommon Stock | 3,500 | $56.33 | $197,155.00 |
DisclosureSEC source: 0001209191-13-022861 · doc4.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,880 Read SEC document |
| April 15, 2013 Filed Apr 16, 2013 15:46 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
SaleCommon Stock | 5,000 | $57.10 | $285,500.00 |
DisclosureSEC source: 0001209191-13-021441 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,875 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2013. F2 · price: This transaction was executed in multiple trades at prices ranging from $57.09 to $57.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 29, 2013 Filed Mar 29, 2013 18:04 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 157 | $54.66 | $8,581.62 |
DisclosureSEC source: 0001209191-13-018969 · doc4.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,188 Read SEC document |
| March 26, 2013 Filed Mar 26, 2013 17:03 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
SaleCommon Stock | 5,000 | $56.00 | $280,000.00 |
DisclosureSEC source: 0001209191-13-018347 · doc4.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,380 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2013. Read SEC document |
| March 12, 2013 Filed Mar 13, 2013 15:21 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
SaleCommon Stock | 19,000 | $55.38 | $1,052,220.00 |
DisclosureSEC source: 0001209191-13-016142 · doc4.xml · nonDerivative · entry 1 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,253 F1 · price: This transaction was executed in multiple trades at prices ranging from $55.33 to $55.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2013 Filed Jan 31, 2014 15:46 UTC |
LECHLEITER JOHN CDirector · Chairman, President and CEO
|
GiftCommon Stock | 457 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000045 · wf-form5_139118320073486.xml · nonDerivative · entry 2 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447,008 Read SEC document |
| February 28, 2013 Filed Mar 1, 2013 14:27 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 158 | $54.18 | $8,560.44 |
DisclosureSEC source: 0001209191-13-012596 · doc4.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,881 Read SEC document |
| February 20, 2013 Filed Jan 31, 2014 15:46 UTC |
LECHLEITER JOHN CDirector · Chairman, President and CEO
|
GiftCommon Stock | 19,585 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000045 · wf-form5_139118320073486.xml · nonDerivative · entry 1 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447,465 Read SEC document |
| February 15, 2013 Filed Jan 31, 2014 15:47 UTC |
Rice Derica WEVP-Global Services and CFO
|
GiftCommon Stock | 52,605 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000048 · wf-form5_139118325651089.xml · nonDerivative · entry 2 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 273,850 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| February 15, 2013 Filed Jan 31, 2014 15:47 UTC |
Rice Derica WEVP-Global Services and CFO
|
GiftCommon Stock | 52,605 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000048 · wf-form5_139118325651089.xml · nonDerivative · entry 1 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| February 08, 2013 Filed Feb 11, 2013 20:59 UTC |
Ricks David ASVP and Pres, Lilly Bio-Meds
|
SaleCommon Stock | 3,000 | $53.91 | $161,730.00 |
DisclosureSEC source: 0001209191-13-007676 · doc4.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,941 Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 14:29 UTC |
Rice Derica WEVP-Global Services and CFO
|
SaleCommon Stock | 29,646 | $54.21 | $1,607,109.66 |
DisclosureSEC source: 0001209191-13-006950 · doc4.xml · nonDerivative · entry 1 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,605 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 21, 2012. F2 · price: This transaction was executed in multiple trades at prices ranging from $54.18 to $54.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:23 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
Exercise / conversionRestricted Stock Unit · Derivative | 31,768 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005976 · doc4.xml · derivative · entry 4 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,768 shares Expires 2013-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:23 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
Tax withholdingCommon Stock | 14,922 | $53.69 | $801,162.18 |
DisclosureSEC source: 0001209191-13-005976 · doc4.xml · nonDerivative · entry 2 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,875 Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:23 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
Exercise / conversionCommon Stock | 31,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005976 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:25 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 132,367 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005980 · doc4.xml · derivative · entry 7 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 132,367 shares Expires 2013-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:25 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
Tax withholdingCommon Stock | 62,173 | $53.69 | $3,338,068.37 |
DisclosureSEC source: 0001209191-13-005980 · doc4.xml · nonDerivative · entry 2 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,050 Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:25 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
Exercise / conversionCommon Stock | 132,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005980 · doc4.xml · nonDerivative · entry 1 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:26 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
Exercise / conversionRestricted Stock Unit · Derivative | 33,334 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005985 · doc4.xml · derivative · entry 7 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Stock Units vests in three equal annual installments as follows: 33,333 on February 1, 2011; 33,333 on February 1, 2012; and 33,334 on February 1, 2013. F1 · derivative.expiration_date: The Restricted Stock Units vests in three equal annual installments as follows: 33,333 on February 1, 2011; 33,333 on February 1, 2012; and 33,334 on February 1, 2013. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:26 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
Exercise / conversionRestricted Stock Unit · Derivative | 44,122 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005985 · doc4.xml · derivative · entry 6 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,122 shares Expires 2013-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:26 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
Tax withholdingCommon Stock | 15,657 | $53.69 | $840,624.33 |
DisclosureSEC source: 0001209191-13-005985 · doc4.xml · nonDerivative · entry 4 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,253 Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:26 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
Exercise / conversionCommon Stock | 33,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005985 · doc4.xml · nonDerivative · entry 3 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:26 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
Tax withholdingCommon Stock | 20,725 | $53.69 | $1,112,725.25 |
DisclosureSEC source: 0001209191-13-005985 · doc4.xml · nonDerivative · entry 2 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,576 Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:26 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
Exercise / conversionCommon Stock | 44,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005985 · doc4.xml · nonDerivative · entry 1 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:27 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
Exercise / conversionRestricted Stock Unit · Derivative | 22,943 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005987 · doc4.xml · derivative · entry 7 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,943 shares Expires 2013-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:27 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
SaleCommon Stock | 5,000 | $54.28 | $271,400.00 |
DisclosureSEC source: 0001209191-13-005987 · doc4.xml · nonDerivative · entry 3 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,380 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2013. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:27 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
Exercise / conversionCommon Stock | 22,943 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005987 · doc4.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:27 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
Tax withholdingCommon Stock | 10,777 | $53.69 | $578,617.13 |
DisclosureSEC source: 0001209191-13-005987 · doc4.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,437 Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:28 UTC |
Peterson Barton RSr. VP, Corp. Affairs & Comm.
|
Exercise / conversionRestricted Stock Unit · Derivative | 14,119 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005990 · doc4.xml · derivative · entry 4 Peterson Barton R · CIK 0001466550 · Sr. VP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,119 shares Expires 2013-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:28 UTC |
Peterson Barton RSr. VP, Corp. Affairs & Comm.
|
Tax withholdingCommon Stock | 6,632 | $53.69 | $356,072.08 |
DisclosureSEC source: 0001209191-13-005990 · doc4.xml · nonDerivative · entry 2 Peterson Barton R · CIK 0001466550 · Sr. VP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,056 Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:28 UTC |
Peterson Barton RSr. VP, Corp. Affairs & Comm.
|
Exercise / conversionCommon Stock | 14,119 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005990 · doc4.xml · nonDerivative · entry 1 Peterson Barton R · CIK 0001466550 · Sr. VP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:30 UTC |
Rice Derica WEVP-Global Services and CFO
|
Exercise / conversionRestricted Stock Unit · Derivative | 52,947 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005996 · doc4.xml · derivative · entry 6 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,947 shares Expires 2013-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:30 UTC |
Rice Derica WEVP-Global Services and CFO
|
Tax withholdingCommon Stock | 24,541 | $53.69 | $1,317,606.29 |
DisclosureSEC source: 0001209191-13-005996 · doc4.xml · nonDerivative · entry 2 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,251 Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:30 UTC |
Rice Derica WEVP-Global Services and CFO
|
Exercise / conversionCommon Stock | 52,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005996 · doc4.xml · nonDerivative · entry 1 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:31 UTC |
Simmons Jeffrey NSVP&Pres.,Elanco Animal Health
|
Exercise / conversionRestricted Stock Unit · Derivative | 17,649 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005997 · doc4.xml · derivative · entry 4 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres.,Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,649 shares Expires 2013-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:31 UTC |
Simmons Jeffrey NSVP&Pres.,Elanco Animal Health
|
Tax withholdingCommon Stock | 8,181 | $53.69 | $439,237.89 |
DisclosureSEC source: 0001209191-13-005997 · doc4.xml · nonDerivative · entry 2 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres.,Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,385 Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:31 UTC |
Simmons Jeffrey NSVP&Pres.,Elanco Animal Health
|
Exercise / conversionCommon Stock | 17,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005997 · doc4.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres.,Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:33 UTC |
Tapiero JacquesSVP&Pres., Emerging Markets
|
Exercise / conversionRestricted Stock Unit · Derivative | 17,649 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-006000 · doc4.xml · derivative · entry 5 Tapiero Jacques · CIK 0001479078 · SVP&Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,649 shares Expires 2013-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:33 UTC |
Tapiero JacquesSVP&Pres., Emerging Markets
|
Tax withholdingCommon Stock | 8,181 | $53.69 | $439,237.89 |
DisclosureSEC source: 0001209191-13-006000 · doc4.xml · nonDerivative · entry 2 Tapiero Jacques · CIK 0001479078 · SVP&Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,802 Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:33 UTC |
Tapiero JacquesSVP&Pres., Emerging Markets
|
Exercise / conversionCommon Stock | 17,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-006000 · doc4.xml · nonDerivative · entry 1 Tapiero Jacques · CIK 0001479078 · SVP&Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2013 Filed Feb 4, 2013 21:34 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 161 | $53.44 | $8,603.84 |
DisclosureSEC source: 0001209191-13-006001 · doc4.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,723 Read SEC document |
| January 30, 2013 Filed Jan 30, 2013 20:42 UTC |
Tapiero JacquesSVP&Pres., Emerging Markets
|
SaleCommon Stock | 15,000 | $54.14 | $812,100.00 |
DisclosureSEC source: 0001209191-13-005141 · doc4.xml · nonDerivative · entry 1 Tapiero Jacques · CIK 0001479078 · SVP&Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,334 Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:42 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
GrantCommon Stock | 1,367 | $53.21 | $72,738.07 |
DisclosureSEC source: 0001209191-13-004978 · doc4.xml · nonDerivative · entry 1 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,034 Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:43 UTC |
Crowe Maria APresident, Mfg. Operations
|
GrantCommon Stock | 13,459 | $53.21 | $716,153.39 |
DisclosureSEC source: 0001209191-13-004982 · doc4.xml · nonDerivative · entry 1 Crowe Maria A · CIK 0001538603 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,178 Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:44 UTC |
Fry Stephen FSVP, HR & Diversity
|
GrantRestricted Stock Unit · Derivative | 9,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-004985 · doc4.xml · derivative · entry 3 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,405 Underlying: Common Stock · 9,405 shares Expires 2014-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:44 UTC |
Fry Stephen FSVP, HR & Diversity
|
GrantCommon Stock | 5,124 | $53.21 | $272,648.04 |
DisclosureSEC source: 0001209191-13-004985 · doc4.xml · nonDerivative · entry 1 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,769 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.